Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E is a research paper published in JCO Precision Oncology (2024). On theSindex it has a DataRank of 0.104. It has been cited 1 time, with 1 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.104
From this paper's citation signal
Citation Network Contribution
0
From 0 citing papers with measurable signal
This paper's DataRank is currently driven only by its base citation score. None of the citing papers had measurable citation signal.
Learn more about DataRank methodology →NCI NIH HHS
Grant: U10 CA180794
NCI NIH HHS
Grant: U24 CA196172
NCI NIH HHS
Grant: UG1 CA233160
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: UG1 CA233290
NCI NIH HHS
Grant: UG1 CA233302
NCI NIH HHS
Grant: UG1 CA233270
NCI NIH HHS
Grant: U10 CA180820
NCI NIH HHS
Grant: T32 CA009207
NCI NIH HHS
Grant: UG1 CA233180
NCI NIH HHS
Grant: U10 CA180888
NCI NIH HHS
Grant: UG1 CA233341
MeSH Terms